Status:
COMPLETED
The Impact of Carvedilol Posology on Clinically Significant Portal Hypertension
Lead Sponsor:
Centro Hospitalar De São João, E.P.E.
Conditions:
Clinically Significant Portal Hypertension
Eligibility:
All Genders
18-77 years
Phase:
NA
Brief Summary
Carvedilol has emerged as the preferred non-selective β-blocker (NSBB) for treating portal hypertension. However, there is still a debate in dosing regimen, specially regarding dose interval, with a p...
Eligibility Criteria
Inclusion
- patients with CSPH (defined as a LSM 25 kPa or SSM over 45kPa prior to introduction of carvedilol)
Exclusion
- Non-responders to non-selective β-blockers (NSBB)
- NSBB other than carvedilol
- Dosing regimen other than twice daily
- No SSM or LSM within 3 months prior to the beginning of the study
- Body mass index (BMI) \> 30 m/kg2
- Contraindications to NSBB use
- Portal venous thrombosis
- Refusal to participate in the study
- Failure to comply to the study regimen
Key Trial Info
Start Date :
June 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT06015373
Start Date
June 1 2023
End Date
July 31 2023
Last Update
August 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Hospitalar de Trás os Montes e Alto Douro
Vila Real, Lordelo, Portugal, 5000-508